Titre : Motifs et domaines d'intéraction protéique

Motifs et domaines d'intéraction protéique : Questions médicales fréquentes

Termes MeSH sélectionnés :

Clinical Coding
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Motifs et domaines d'intéraction protéique : Questions médicales les plus fréquentes", "headline": "Motifs et domaines d'intéraction protéique : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Motifs et domaines d'intéraction protéique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-22", "dateModified": "2025-04-17", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Motifs et domaines d'intéraction protéique" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Éléments structuraux des protéines", "url": "https://questionsmedicales.fr/mesh/D000072416", "about": { "@type": "MedicalCondition", "name": "Éléments structuraux des protéines", "code": { "@type": "MedicalCode", "code": "D000072416", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Domaine B30.2-SPRY", "alternateName": "B30.2-SPRY Domain", "url": "https://questionsmedicales.fr/mesh/D000071197", "about": { "@type": "MedicalCondition", "name": "Domaine B30.2-SPRY", "code": { "@type": "MedicalCode", "code": "D000071197", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.290" } } }, { "@type": "MedicalWebPage", "name": "Domaine BTB-POZ", "alternateName": "BTB-POZ Domain", "url": "https://questionsmedicales.fr/mesh/D000071757", "about": { "@type": "MedicalCondition", "name": "Domaine BTB-POZ", "code": { "@type": "MedicalCode", "code": "D000071757", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.343" } } }, { "@type": "MedicalWebPage", "name": "Superfamille des domaines de mort", "alternateName": "Death Domain Superfamily", "url": "https://questionsmedicales.fr/mesh/D000071458", "about": { "@type": "MedicalCondition", "name": "Superfamille des domaines de mort", "code": { "@type": "MedicalCode", "code": "D000071458", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.395" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Domaine d'activation et de recrutement des caspases", "alternateName": "Caspase Activation and Recruitment Domain", "url": "https://questionsmedicales.fr/mesh/D000071476", "about": { "@type": "MedicalCondition", "name": "Domaine d'activation et de recrutement des caspases", "code": { "@type": "MedicalCode", "code": "D000071476", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.395.250" } } }, { "@type": "MedicalWebPage", "name": "Domaine de mort", "alternateName": "Death Domain", "url": "https://questionsmedicales.fr/mesh/D000071459", "about": { "@type": "MedicalCondition", "name": "Domaine de mort", "code": { "@type": "MedicalCode", "code": "D000071459", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.395.500" } } }, { "@type": "MedicalWebPage", "name": "Domaine effecteur de mort", "alternateName": "Death Effector Domain", "url": "https://questionsmedicales.fr/mesh/D000071461", "about": { "@type": "MedicalCondition", "name": "Domaine effecteur de mort", "code": { "@type": "MedicalCode", "code": "D000071461", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.395.750" } } }, { "@type": "MedicalWebPage", "name": "Domaine pyrine", "alternateName": "Pyrin Domain", "url": "https://questionsmedicales.fr/mesh/D000071196", "about": { "@type": "MedicalCondition", "name": "Domaine pyrine", "code": { "@type": "MedicalCode", "code": "D000071196", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.395.875" } } } ] }, { "@type": "MedicalWebPage", "name": "Domaines FERM", "alternateName": "FERM Domains", "url": "https://questionsmedicales.fr/mesh/D000075926", "about": { "@type": "MedicalCondition", "name": "Domaines FERM", "code": { "@type": "MedicalCode", "code": "D000075926", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.422" } } }, { "@type": "MedicalWebPage", "name": "Domaines MYND", "alternateName": "MYND Domains", "url": "https://questionsmedicales.fr/mesh/D000074608", "about": { "@type": "MedicalCondition", "name": "Domaines MYND", "code": { "@type": "MedicalCode", "code": "D000074608", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.474" } } }, { "@type": "MedicalWebPage", "name": "Domaines PDZ", "alternateName": "PDZ Domains", "url": "https://questionsmedicales.fr/mesh/D054731", "about": { "@type": "MedicalCondition", "name": "Domaines PDZ", "code": { "@type": "MedicalCode", "code": "D054731", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.500" } } }, { "@type": "MedicalWebPage", "name": "Domaines à doigts de zinc de type RING", "alternateName": "RING Finger Domains", "url": "https://questionsmedicales.fr/mesh/D054829", "about": { "@type": "MedicalCondition", "name": "Domaines à doigts de zinc de type RING", "code": { "@type": "MedicalCode", "code": "D054829", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.625" } } }, { "@type": "MedicalWebPage", "name": "Domaine d'homologie SRC", "alternateName": "src Homology Domains", "url": "https://questionsmedicales.fr/mesh/D018909", "about": { "@type": "MedicalCondition", "name": "Domaine d'homologie SRC", "code": { "@type": "MedicalCode", "code": "D018909", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.750" } } }, { "@type": "MedicalWebPage", "name": "Motif stérile alpha", "alternateName": "Sterile Alpha Motif", "url": "https://questionsmedicales.fr/mesh/D000071682", "about": { "@type": "MedicalCondition", "name": "Motif stérile alpha", "code": { "@type": "MedicalCode", "code": "D000071682", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.813" } } }, { "@type": "MedicalWebPage", "name": "Domaine Tudor", "alternateName": "Tudor Domain", "url": "https://questionsmedicales.fr/mesh/D000071856", "about": { "@type": "MedicalCondition", "name": "Domaine Tudor", "code": { "@type": "MedicalCode", "code": "D000071856", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.844" } } }, { "@type": "MedicalWebPage", "name": "Domaines WW", "alternateName": "WW Domains", "url": "https://questionsmedicales.fr/mesh/D000074585", "about": { "@type": "MedicalCondition", "name": "Domaines WW", "code": { "@type": "MedicalCode", "code": "D000074585", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.820.709.275.750.500.937" } } } ], "about": { "@type": "MedicalCondition", "name": "Motifs et domaines d'intéraction protéique", "alternateName": "Protein Interaction Domains and Motifs", "code": { "@type": "MedicalCode", "code": "D054730", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Ylva Ivarsson", "url": "https://questionsmedicales.fr/author/Ylva%20Ivarsson", "affiliation": { "@type": "Organization", "name": "Department of Chemistry-BMC, Uppsala University, Box 576, SE-751 23 Uppsala, Sweden. Electronic address: Yiva.ivarson@kemi.uu.se." } }, { "@type": "Person", "name": "Sobia Idrees", "url": "https://questionsmedicales.fr/author/Sobia%20Idrees", "affiliation": { "@type": "Organization", "name": "School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia." } }, { "@type": "Person", "name": "Keshav Raj Paudel", "url": "https://questionsmedicales.fr/author/Keshav%20Raj%20Paudel", "affiliation": { "@type": "Organization", "name": "Centre for Inflammation, Centenary Institute and Faculty of Science, School of Life Sciences, University of Technology Sydney, Australia." } }, { "@type": "Person", "name": "Per Jemth", "url": "https://questionsmedicales.fr/author/Per%20Jemth", "affiliation": { "@type": "Organization", "name": "Department of Medical Biochemistry and Microbiology, Uppsala University, BMC Box 582, SE-75123 Uppsala, Sweden. Electronic address: Per.Jemth@imbim.uu.se." } }, { "@type": "Person", "name": "Norman E Davey", "url": "https://questionsmedicales.fr/author/Norman%20E%20Davey", "affiliation": { "@type": "Organization", "name": "Division of Cancer Biology, The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Hierarchical label-wise attention transformer model for explainable ICD coding.", "datePublished": "2022-08-20", "url": "https://questionsmedicales.fr/article/35995108", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jbi.2022.104161" } }, { "@type": "ScholarlyArticle", "name": "Interpreting and coding causal relationships for quality and safety using ICD-11.", "datePublished": "2023-11-16", "url": "https://questionsmedicales.fr/article/37974148", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12911-023-02363-5" } }, { "@type": "ScholarlyArticle", "name": "Coding rules for uncertain and \"ruled out\" diagnoses in ICD-10 and ICD-11.", "datePublished": "2024-09-27", "url": "https://questionsmedicales.fr/article/39334213", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12911-024-02661-6" } }, { "@type": "ScholarlyArticle", "name": "Validation of diagnostic coding for bronchiectasis in an electronic health record system in Hong Kong.", "datePublished": "2023-05-28", "url": "https://questionsmedicales.fr/article/37169360", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/pds.5638" } }, { "@type": "ScholarlyArticle", "name": "Association of Insurance Mix and Diagnostic Coding Practices in New York State Hospitals.", "datePublished": "2022-09-02", "url": "https://questionsmedicales.fr/article/36218926", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1001/jamahealthforum.2022.2919" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes chimiques", "item": "https://questionsmedicales.fr/mesh/D055598" }, { "@type": "ListItem", "position": 3, "name": "Phénomènes biochimiques", "item": "https://questionsmedicales.fr/mesh/D001669" }, { "@type": "ListItem", "position": 4, "name": "Conformation moléculaire", "item": "https://questionsmedicales.fr/mesh/D008968" }, { "@type": "ListItem", "position": 5, "name": "Conformation des protéines", "item": "https://questionsmedicales.fr/mesh/D011487" }, { "@type": "ListItem", "position": 6, "name": "Éléments structuraux des protéines", "item": "https://questionsmedicales.fr/mesh/D000072416" }, { "@type": "ListItem", "position": 7, "name": "Motifs et domaines d'intéraction protéique", "item": "https://questionsmedicales.fr/mesh/D054730" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Motifs et domaines d'intéraction protéique - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Motifs et domaines d'intéraction protéique", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-07", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Motifs et domaines d'intéraction protéique", "description": "Comment identifier un domaine d'interaction protéique ?\nQuels tests sont utilisés pour analyser les interactions protéiques ?\nLes motifs d'interaction peuvent-ils être prédits ?\nQuels marqueurs indiquent une interaction protéique ?\nComment les mutations affectent-elles les interactions protéiques ?", "url": "https://questionsmedicales.fr/mesh/D054730?mesh_terms=Clinical+Coding&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Motifs et domaines d'intéraction protéique", "description": "Quels symptômes indiquent une dysfonction protéique ?\nLes interactions protéiques peuvent-elles causer des maladies ?\nComment les maladies génétiques affectent-elles les interactions ?\nQuels signes cliniques sont liés aux troubles d'interaction ?\nLes infections peuvent-elles perturber les interactions protéiques ?", "url": "https://questionsmedicales.fr/mesh/D054730?mesh_terms=Clinical+Coding&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Motifs et domaines d'intéraction protéique", "description": "Comment prévenir les maladies liées aux interactions protéiques ?\nLes dépistages sont-ils utiles pour les troubles protéiques ?\nL'éducation sur les interactions protéiques est-elle importante ?\nLes vaccins influencent-ils les interactions protéiques ?\nComment le stress affecte-t-il les interactions protéiques ?", "url": "https://questionsmedicales.fr/mesh/D054730?mesh_terms=Clinical+Coding&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Motifs et domaines d'intéraction protéique", "description": "Quels traitements ciblent les interactions protéiques ?\nComment la thérapie génique influence-t-elle les interactions ?\nLes inhibiteurs de protéines sont-ils efficaces ?\nComment les traitements ciblent-ils les motifs d'interaction ?\nLes thérapies combinées sont-elles bénéfiques ?", "url": "https://questionsmedicales.fr/mesh/D054730?mesh_terms=Clinical+Coding&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Motifs et domaines d'intéraction protéique", "description": "Quelles complications peuvent survenir avec des interactions anormales ?\nLes complications sont-elles réversibles ?\nComment les interactions affectent-elles le vieillissement ?\nLes maladies auto-immunes sont-elles liées aux interactions ?\nLes troubles métaboliques sont-ils causés par des interactions ?", "url": "https://questionsmedicales.fr/mesh/D054730?mesh_terms=Clinical+Coding&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Motifs et domaines d'intéraction protéique", "description": "Quels facteurs augmentent le risque de troubles protéiques ?\nLe vieillissement est-il un facteur de risque ?\nLes infections virales influencent-elles les interactions ?\nLe mode de vie peut-il affecter les interactions protéiques ?\nLes facteurs environnementaux jouent-ils un rôle ?", "url": "https://questionsmedicales.fr/mesh/D054730?mesh_terms=Clinical+Coding&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier un domaine d'interaction protéique ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'identification se fait par des méthodes bioinformatiques et des expériences de biologie moléculaire." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour analyser les interactions protéiques ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent le co-immunoprécipitation et les essais de double hybride." } }, { "@type": "Question", "name": "Les motifs d'interaction peuvent-ils être prédits ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des outils bioinformatiques permettent de prédire les motifs d'interaction dans les protéines." } }, { "@type": "Question", "name": "Quels marqueurs indiquent une interaction protéique ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des changements de conformation ou des complexes protéiques stables peuvent indiquer une interaction." } }, { "@type": "Question", "name": "Comment les mutations affectent-elles les interactions protéiques ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les mutations peuvent altérer la structure des motifs, perturbant ainsi les interactions normales." } }, { "@type": "Question", "name": "Quels symptômes indiquent une dysfonction protéique ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes variés comme la fatigue, des troubles métaboliques ou des maladies auto-immunes." } }, { "@type": "Question", "name": "Les interactions protéiques peuvent-elles causer des maladies ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des interactions anormales peuvent contribuer à des maladies comme le cancer ou Alzheimer." } }, { "@type": "Question", "name": "Comment les maladies génétiques affectent-elles les interactions ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent entraîner des défauts dans les motifs d'interaction, perturbant les fonctions cellulaires." } }, { "@type": "Question", "name": "Quels signes cliniques sont liés aux troubles d'interaction ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme l'inflammation, la douleur ou des anomalies neurologiques peuvent apparaître." } }, { "@type": "Question", "name": "Les infections peuvent-elles perturber les interactions protéiques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains pathogènes modifient les interactions protéiques pour favoriser leur survie." } }, { "@type": "Question", "name": "Comment prévenir les maladies liées aux interactions protéiques ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et un mode de vie sain peuvent réduire les risques." } }, { "@type": "Question", "name": "Les dépistages sont-ils utiles pour les troubles protéiques ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des dépistages précoces peuvent aider à identifier des risques de maladies génétiques." } }, { "@type": "Question", "name": "L'éducation sur les interactions protéiques est-elle importante ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, comprendre les interactions peut aider à prévenir des maladies et à promouvoir la santé." } }, { "@type": "Question", "name": "Les vaccins influencent-ils les interactions protéiques ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les vaccins peuvent moduler les interactions immunitaires, renforçant la réponse du corps." } }, { "@type": "Question", "name": "Comment le stress affecte-t-il les interactions protéiques ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Le stress peut altérer les interactions protéiques, affectant la santé globale et le bien-être." } }, { "@type": "Question", "name": "Quels traitements ciblent les interactions protéiques ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme les inhibiteurs de protéines ou des anticorps monoclonaux sont utilisés." } }, { "@type": "Question", "name": "Comment la thérapie génique influence-t-elle les interactions ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut corriger des mutations, rétablissant ainsi des interactions protéiques normales." } }, { "@type": "Question", "name": "Les inhibiteurs de protéines sont-ils efficaces ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent bloquer des interactions spécifiques, offrant des options thérapeutiques." } }, { "@type": "Question", "name": "Comment les traitements ciblent-ils les motifs d'interaction ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Ils visent à modifier ou à bloquer des motifs spécifiques pour restaurer la fonction cellulaire." } }, { "@type": "Question", "name": "Les thérapies combinées sont-elles bénéfiques ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent cibler plusieurs interactions protéiques, améliorant l'efficacité du traitement." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des interactions anormales ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des cancers, des maladies neurodégénératives ou des troubles métaboliques." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec un traitement approprié, d'autres non." } }, { "@type": "Question", "name": "Comment les interactions affectent-elles le vieillissement ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des interactions protéiques altérées peuvent accélérer le vieillissement cellulaire et tissulaire." } }, { "@type": "Question", "name": "Les maladies auto-immunes sont-elles liées aux interactions ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des interactions anormales peuvent déclencher des réponses auto-immunes dans l'organisme." } }, { "@type": "Question", "name": "Les troubles métaboliques sont-ils causés par des interactions ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des interactions protéiques défectueuses peuvent entraîner des déséquilibres métaboliques." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de troubles protéiques ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme la génétique, l'environnement et le mode de vie influencent le risque." } }, { "@type": "Question", "name": "Le vieillissement est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le vieillissement peut affecter la stabilité et la fonction des interactions protéiques." } }, { "@type": "Question", "name": "Les infections virales influencent-elles les interactions ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections virales peuvent perturber les interactions protéiques, augmentant les risques." } }, { "@type": "Question", "name": "Le mode de vie peut-il affecter les interactions protéiques ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation déséquilibrée et le manque d'exercice peuvent altérer les interactions." } }, { "@type": "Question", "name": "Les facteurs environnementaux jouent-ils un rôle ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des toxines ou des polluants peuvent affecter les interactions protéiques et la santé." } } ] } ] }

Sous-catégories

15 au total

Sources (10000 au total)

Validation of diagnostic coding for bronchiectasis in an electronic health record system in Hong Kong.

Electronic medical record (EMR) databases can facilitate epidemiology research in various diseases including bronchiectasis. Given the diagnostic challenges of bronchiectasis, the validity of the codi... Adult patients who had the diagnosis of bronchiectasis input from Queen Mary Hospital in 2011-2020 were identified using the ICD-9 code of 494 by CDARS. All patients who had high resolution computed t... A total of 19 617 patients who had the diagnostic code of bronchiectasis among all public hospitals in Hong Kong and 1866 in Queen Mary Hospital in the same period. Six hundred and forty-eight cases w... This was the first ICD-9 coding validation for bronchiectasis in Hong Kong CDARS. Our study demonstrated that using ICD-9 code of 494 was reliable to support utility of CDARS database for further clin...

Association of Insurance Mix and Diagnostic Coding Practices in New York State Hospitals.

Given higher reimbursement rates, hospitals primarily serving privately insured patients may invest more in intensive coding than hospitals serving publicly insured patients. This may lead these hospi... To estimate whether, for the same Medicaid enrollee with multiple hospitalizations, a hospital's share of privately insured patients is associated with the number of diagnoses on claims.... This cross-sectional study used patient-level fixed effects regression models on inpatient Medicaid claims from Medicaid enrollees with at least 2 admissions in at least 2 different hospitals in New Y... The annual share of privately insured patients at the admitting hospital.... Number of diagnostic codes per admission. Probability of diagnoses being from a list of conditions shown to be intensely coded in response to payment incentives.... This analysis included 1 614 630 hospitalizations for Medicaid-insured patients (mean [SD] age, 48.2 [20.1] years; 829 684 [51.4%] women and 784 946 [48.6%] men). Overall, 74 998 were Asian (4.6%), 46... In this cross-sectional study of Medicaid enrollees, admission to a hospital with a higher private payer share was associated with more diagnoses on Medicaid claims. This suggests payment policy may d...

An assessment of completeness and medical coding of Medicare Advantage hospitalizations in two national data sets.

To compare the Encounter Data System (EDS) and Medicare Provider Analysis and Review (MedPAR) completeness and medical coding of Medicare Advantage hospitalizations.... FY 2016-FY 2019 data limited to hospitals paid under Medicare's Inpatient Prospective Payment System.... Secondary data analysis.... Completeness of EDS and MedPAR data was estimated using the total number of unique hospitalizations in both data sources as denominator. Deriving this denominator involved matching cases in the EDS an... EDS hospitalizations' completeness increased steadily each year from 90% to 93%, driven by the 23 largest Medicare Advantage Organizations, which account for 83% of total cases. MedPAR completeness wa... The EDS has a completeness advantage over MedPAR for studies of non-teaching disproportionate share (DSH) hospitals and individual hospitals generally. MedPAR is only slightly less complete for hospit...

Model correction of diagnostic coding-based RSV incidence for children 0-4 years in the US.

Although administrative claims data have a high degree of completeness, not all medically attended Respiratory Syncytial Virus-associated lower respiratory tract infections (RSV-LRTIs) are tested or c... We estimated the weekly incidence of LRTI (inpatient, outpatient, and total) for children 0-4 years using 2011-2019 commercial insurance claims, stratified by HHS region, matched to the corresponding ... Approximately 42% of predicted RSV cases were coded in claims data. Across all regions, the percentage of LRTI attributable to RSV were 15-43%, 10-31%, and 10-31% of inpatient, outpatient, and combine... Underestimation based on coding in claims data may be addressed by NREVSS-based adjustment of claims-based RSV incidence. However, where setting-specific positivity rates is unavailable, we recommend ...

Digitalising the past decades: automated ICD-10 coding of unstructured free text dermatological diagnoses.

Current digital medical databases record systematically coded diagnoses, but many legacy databases are full of hand-written, free text diagnoses, which can only be meaningfully analysed after mapping ... Therefore, we sought to create an algorithm which maps hand-written German diagnoses from our clinical photography database to ICD-10 diagnosis codes, validate its output manually by dermatologists an... Our rule-based algorithm mapped 50,884 unprocessed hand-written German free-text diagnoses covering five decades to ICD-10 codes, while reaching an accuracy of 82% against 817 dermatologist-validated ... Using the presented algorithm, it is possible to reliably match hand-written free text of German dermatological diagnoses to ICD-10 codes, thus enabling systematic analysis of legacy databases, making...

Perioperative Myomectomy Outcomes Based on the Current Coding Rules: Comparing Leiomyoma Burden and Surgical Approach.

To assess postoperative outcomes based on surgical approach for myomectomies with increasing leiomyoma burden.... We conducted a retrospective analysis using the American College of Surgeons National Surgical Quality Improvement Program database from 2014 to 2019 of benign myomectomy procedures. These cases were ... Of 8,363 total myomectomy procedures, 3,117 (37.3%) were performed using minimally invasive surgery (MIS) and 5,246 (62.7%) were performed using laparotomy. Among MIS cases, 2,080 (66.7%) were categor... A minimally invasive surgical approach for both smaller and larger myomectomies was associated with fewer minor complications compared with laparotomy. Minimally invasive surgery for larger myomectomi...